FOR U.S. HEALTHCARE PROFESSIONALS ONLY

Well tolerated for acute and
preventive treatment
Most Common (≥2%) Adverse Events
Percentage of patients
that experienced nausea1-3
Percentage of patients
that experienced abdominal pain/dyspepsia1,3
Well tolerated in
preventive study
2% (n=7/370)
discontinued
due to AEs3
Nurtec ODT was not associated with any serious treatment-related AEs in clinical trials.2,3
The transfer of rimegepant into breastmilk is low (<1%).
Long-term safety maintained through 52 weeks1
Up to 18 doses of Nurtec ODT can be taken per month.1
A long-term open label safety study with 1800 patients evaluated rimegepant 75 mg dosed as needed for 52 weeks (N=1514) and dosed every other day plus as needed for 12 weeks (N=286).1,5
Long-term safety was maintained in the long-term open-label safety study1
1800 patients were given multiple doses of rimegepant 75 mg, as needed up to one dose per day, for up to 52 weeks1,6
Enrollment Groups6
History of Moderate to Severe Migraine

2-8 attacks/month (n=1033)
9-14 attacks/month (n=481)
4-14 attacks/month (n=286)
Rimegepant Treatment6
52 weeks as needed up to 1x/daily dosing
(n=1514)
Up to 12 Weeks fixed dosing EOD + PRN dosing
(n=286)
EOD: every other day; PRN: as needed6
Average of 7 .7 doses per 4 weeks/subject for up to 52 weeks (n=1800)6
The ODT and tablet formulations of rimegepant are bioequivalent.2
References: 1. Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. 2. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. 3. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2020;397(10268): 51-60. doi:10.1016/S0140-6736(20)32544-7. 4. Data on File. RIM113. Pfizer Inc. 5. McGinley JS, L'Italien GJ, Thiry AC, et al. Rimegepant 75 mg results in reductions in monthly migraine days: Secondary analysis of a multicenter, open label, long‑term safety study of rimegepant for the acute treatment of migraine. Virtual Poster presented at: American Academy of Neurology 2020 Annual Meeting; 2020. 6. Croop R, Berman G, Kudrow D, et al. Long-term safety of rimegepant 75 mg for the acute treatment of migraine (study 201). Poster presented at: Virtual Annual Scientific Meeting of the American Headache Society; June 13, 2020.